Glaucoma is a leading cause of visual loss and blindness in aging Western populations. Reduction of elevated intraocular pressure is the paramount aim of glaucoma treatment to avoid further progression of the disease. Topical instillation onto the anterior surface of the eye is the desired route of administration for the widely used β-blockers and prostanoids to treat glaucoma. However, there are a considerable number of non-responders (10-20%) in each of the drug classes. The aim of the project is to systematically investigate the impact of individual and genetic variation in drug transporter expression and function for anti-glaucoma therapy in order to better predict the outcome of β-blocker and prostanoid therapy in patients with glaucoma. A particular aim is to characterize the overall expression profile of 60 SLC- and 48 ABC-transporters in different human ocular tissues.